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Abstract
Purpose—Older cancer survivors are a vulnerable population due to an increased risk for 
chronic diseases (e.g., cardiovascular disease) compounded with treatment late-effects and 
declines in physical functioning. Therefore, interventions that reduce chronic disease risk factors 
(i.e., blood pressure, chronic inflammation, & cortisol) are important in this population. Tai Chi 
Chih (TCC) is a mind-body exercise associated with reductions in chronic disease risk factors, but 
*Corresponding Author: Rebecca A. Campo, PhD Program on Integrative Medicine Department of Physical Medicine & 
Rehabilitation University of North Carolina at Chapel Hill CB# 7200 Chapel Hill, NC 27599-7200 rebecca_campo@med.unc.edu. 
Conflict of Interest
All authors declare that they have no conflict of interest.
NIH Public Access
Author Manuscript
J Cancer Surviv. Author manuscript; available in PMC 2016 March 01.
Published in final edited form as:






















has not been examined with older cancer survivors. In a feasibility randomized controlled trial of 
TCC, we examined secondary outcomes of blood pressure, salivary cortisol, and inflammatory 
cytokines (interleukin (IL)-6, IL-12, tumor necrosis factor-α, IL-10, IL-4) due to their implications 
in chronic diseases.
Methods—Sixty-three senior female cancer survivors (Mage=67 years, SD=7.15) with physical 
functioning limitations (SF-12 physical functioning≤80 or role-physical≤72) were randomized to 
12-weeks (60-minutes, three times a week) of TCC or Health Education control (HEC) classes. 
Resting blood pressure, 1-day salivary cortisol samples, and fasting plasma samples for cytokine 
multiplex assays were collected at baseline and 1-week post-intervention.
Results—Controlling for baseline values, the TCC group had significantly lower systolic blood 
pressure (SBP, p=0.002) and cortisol area-under-curve (AUC, p=0.02) at post-intervention than 
the HEC group. There was no intervention effect on inflammatory cytokines (p’s>0.05).
Conclusions—This TCC feasibility trial was associated with significant reductions in SBP and 
cortisol AUC in senior female cancer survivors. Larger, definitive trials are needed to confirm 
these findings.
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Introduction
An estimated 60% of cancer survivors are 65 years of age or older and the number of older 
survivors is projected to increase dramatically by the year 2020 [1]. Senior cancer survivors 
are a particularly vulnerable population because they have an increased risk for the 
development or progression of chronic diseases (e.g., cardiovascular, hypertension, stroke, 
Type 2 diabetes mellitus, arthritis, etc), alongside cancer and/or treatment-related late effects 
(e.g., pain, fatigue, lymphedema, etc.), risks for cancer recurrence and additional primaries, 
and declines in physical functioning [2–7]. Likewise, the coexistence of chronic diseases 
with late effects can accelerate declines in survivors’ health-related quality of life [8, 7] and 
worsen survival prognosis [9]. In senior cancer survivors, this is highly relevant as twice as 
many deaths occur as a result of chronic diseases other than cancer, with cardiovascular 
disease emerging as a leading cause of death[10]. Reported potential causes include lifestyle 
factors (decreased physical activity, increased weight gain), existence of comorbidities (e.g., 
hypertension , Type 2 diabetes mellitus), and treatment-related factors such as the adverse 
cardiac effects associated with chemotherapy and radiation treatment [3, 10–12, 7, 13]. This 
presents a need to intervene on senior cancer survivors’ modifiable risk factors (e.g., 
hypertension, chronic inflammation, lack of physical activity, etc.) that are associated with 
the most common chronic diseases (i.e., cardiovascular) in this population [14, 5]).
Exercise is associated with reductions in chronic disease risk factors [15] and reduced risk of 
cancer recurrence and all-cause mortality in cancer survivors [16, 17, 2, 18]. Unfortunately, 
a majority of older survivors do not meet physical activity recommendations, with female 
survivors older than 60 years of age spending 44% less time in physical activity than those 
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younger than 50 years of age [19]. Tai Chi (TC) is a form of exercise that is also known as 
meditative movement because it combines physical activity with meditation [20]. There are 
various styles of TC, but generally the practice consists of focused, fluid physical 
movements (i.e., balance and shifting of body weight), which are performed in a specified 
order, coordinated with breathing and imagery to relax the mind, strengthen the body, and 
improve the flow of “qi” or life energy [21]. The metabolic equivalents (METs) of TC range 
from an estimated 3.3 METs (Yang-style Tai Chi Chuan) to 2.6 METs (Tai Chi Chih style); 
a moderate-intensity level similar to walking at 2 to 3 miles per hour [22, 23]. For the older 
cancer survivor, TC may be an appealing form of exercise because it consists of repetitive, 
steady movements that are considered safe (i.e., can be performed sitting or standing), easy 
to learn [21, 24], and can be performed in various types of locations (i.e., at home or other 
setting) with little to no cost.
Similar to traditional exercise, TC is associated with improvements in chronic disease risk 
factors such as cardiovascular factors (i.e., reductions in blood pressure (BP), sympathetic 
activity, lipid profiles, endothelial dysfunction) [21, 25–27], insulin markers (i.e., insulin-
like growth factors, maintained insulin levels) [28], chronic inflammation (C-reactive 
protein (CRP) [29, 30], increased cell-mediated immunity to the Shingles virus [31, 32], 
functional capacity [33, 34], bone metabolism benefits [35] , and healthrelated quality of life 
(QOL) [33, 36, 29, 32, 37, 31, 34]. Although the mechanisms for TC influences on 
biological risk factors have not been established, proposed pathways include physical 
activity and stressreduction influences on the hypothalamic – pituitary – adrenal (HPA) axis 
and autonomic nervous system (i.e., decreased sympathetic activity, increased 
parasympathetic activity), which can interact with the immune system via different 
pathways [38–40]. Pro-inflammatory cytokines (such as Tumor necrosis factor (TNF)-α, 
IL-6) trigger downstream release of glucocorticiods (cortisol) via activation of the HPA axis, 
which in turn downregulates pro-inflammatory cytokines and mediates a shift to a T-helper2 
(Th-2) anti-inflammatory cytokine balance [41]. However, chronically elevated cortisol 
levels may also lead to glucocorticoid receptor resistance, thus increasing susceptibility to 
inflammatory-related diseases [42]. This has relevance to senior cancer survivors because 
aging is associated with dysregulation of the immune system and chronic low-grade 
inflammation. Chronic inflammation is a risk factor for cardiovascular disease, linked to 
cancer growth and progression, and a predictor of physical decline and all-cause mortality in 
elderly adults [43, 44, 38, 45–48]. Therefore, reductions in chronic disease risk factors is 
important for reducing older survivor’s increased risk for cardiovascular disease and other 
chronic diseases with underlying chronic inflammation (e.g., arthritis, atherosclerosis, 
anemia, cancer, Alzheimer’s, etc.) [7, 49, 11, 10]. In this study, we examined blood pressure 
because hypertension is a major risk factor for cardiovascular disease [50, 51] and the 
prevalence of cardiovascular disease mortality/morbidity is high among senior cancer 
survivors [49, 10]. Additionally, we examined the pro-inflammatory cytokines IL-12, IL-6, 
TNF-α, and the anti-inflammatory cytokines IL-10 and IL-4 because these are reported by 
researchers to be major cytokines and/or have implications for chronic disease and/or 
cancer-related outcomes [41, 52]. Finally, salivary cortisol was examined due to its role in 
inflammatory responses and chronic disease risk [42, 41, 53].
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In this manuscript, we report on secondary outcomes of BP, salivary cortisol, and 
inflammatory cytokines from a 12-week feasibility RCT of TCC in senior female cancer 
survivors. A prior publication has reported on the RCT’s primary outcomes of feasibility, 
acceptability, and health-related QOL outcomes [54]. In this RCT, we focused on female 
survivors to expand on prior TC trials conducted with breast cancer survivors [28, 36]. 
Additionally, we focused on senior survivors with some physical functioning limitations so 
that these findings would be generalizable to the real-world setting where many older 
survivors are experiencing declines in physical functioning [8]. Although prior RCTs of 
TCC and TC have been conducted with non-cancer senior adults and breast cancer 
survivors, to our knowledge no RCT has examined the effects of a TCC intervention on 
senior female cancer survivors’ chronic disease risk factors.
Methods
Study Design and Participants
The study design was a two-armed, parallel group, feasibility RCT that followed the 
guidelines of the Consolidated Standards of Reporting Trials (CONSORT) statement (Figure 
1) [55]. It was approved by the University of Utah’s Institutional Review Board and 
registered at ClinicalTrials.gov (Identifier NCT01305044). Sample size power calculations 
were based on this feasibility trial’s primary outcomes of health-related QOL (SF-36), which 
have been reported previously [54]. The biomarker outcomes from this study would be used 
to determine the sample size necessary for a larger, definitive RCT.
Senior female cancer survivors (age ≥ 55 years) with physical functioning limitations (SF-12 
subscales: physical functioning ≤80, or role-physical ≤72) were recruited via Huntsman 
Cancer Institute (HCI) Tissue Resource & Applications Core registry (TRAC), Huntsman 
Cancer Hospital clinics, and community advertisements. The cut-off values for the SF-12 
physical functioning and role-physical subscales were based on a TCC trial in which low 
functioning older adults (using similar SF-12 cut-off values) benefited the most from the 
intervention [32]. As mentioned prior, we focused on survivors with physical functioning 
limitations so that these findings would be generalizable to the real-world setting where 
many older survivors are experiencing declines in physical functioning [8]. Additional 
inclusion criteria were: 1) Diagnosis of solid tumor cancer, stages I-III, 2) ≥3 months since 
cancer treatment completion (exception of hormone therapy), with no detectable cancer, 3) 
not currently engaged in focused, intense physical activity for 30 minutes or more a day, for 
≥ 3 days per week, and 4) no experience with Tai Chi, yoga, or similar types of mind-body 
exercises within the past six months. Further details of eligibility criteria are also reported in 
prior publication [54]. All participants provided written informed consent.
Measures
We examined one-week post-intervention outcomes in BP, salivary cortisol, and 
inflammatory cytokines because acute effects of a 12-week TCC intervention were of 
interest. This timeframe has also been used in other TCC interventions for older adults that 
examined biomarker outcomes [32, 30].
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Blood Pressure—Resting systolic (SBP) and diastolic blood pressure (DBP) were 
assessed with an oscillating blood pressure cuff (Omron 5 Series model) at baseline (prior to 
randomization) and at one week post-intervention. BP was measured in the morning of 
participants’ physical assessment session1, after the participant had been seated for 
approximately five minutes.
Cortisol—Five saliva samples (awakening, 30 minutes after awakening, noon, 5pm, & 
10pm) were collected on a weekend day at baseline and one-week post-intervention with 
Salivette® swabs (Sarstedt AG & Co.). Participants were asked to refrain from brushing 
teeth, eating, or drinking 30 minutes prior to collection. Salivary cortisol samples were 
assayed at the Kirschbaum Biopsychology Laboratory at Technical University of Dresden, 
Germany. The samples were prepared for biochemical analysis by centrifuging at 3000 rpm 
for 5 min, which resulted in a clear supernatant of low viscosity. Salivary free cortisol 
concentrations were determined employing a chemiluminescence immunoassay (CLIA) with 
high sensitivity of 0.16 ng/ml (IBL; Hamburg, Germany). Intra- and inter-assay coefficients 
of variation were below 8%.
Inflammatory Cytokines—Fasting blood samples were drawn on the morning of the 
study’s physical assessment sessions1 at baseline and one-week post-intervention. Prior to 
the blood draws, we ensured that participants did have illness or fever at the time of the 
blood draw. Plasma aliquots were assayed at the Associated Regional and University 
Pathologists (ARUP) Institute for Clinical and Experimental Pathology in Salt Lake City, 
Utah with a multiplexed cytokine assay developed at the Institute using a standard sandwich 
capture format [56]. This multiplex assay has a large dynamic range with good sensitivity, 
measuring from less than 10 to 10,000 pg/mL [57]. As mentioned prior, we analyzed the 
pro-inflammatory cytokines IL-12, IL-6, TNF-α, and the anti-inflammatory cytokines IL-10 
and IL-4 because these are reported by researchers to be major cytokines and/or have 
implications for cancer-related outcomes [41, 52].
Intervention
After completion of the baseline survey, HCI’s Research Informatics Shared Resource 
randomized participants in blocks of 2 to 4 to TCC or Health Education Classes (HEC). A 
single-blinded design was not followed because informed consent procedures required that 
participants be informed that they would be randomly assigned to either TCC or HEC. 
Statisticians were blinded to study group allocation. The TCC and HEC each comprised 60 
minute sessions, three days per week, over a 12-week period (i.e., total of 36 sessions). The 
class frequency and intervention duration was based on an amount found to be efficacious 
for physical function outcomes in TCC and other TC forms involving 20–25 movements 
[21, 34, 58]. This was also viewed as an acceptable length in this senior sample for whom 
time commitment (i.e., time required to attend classes and for traveling) is a barrier to 
engaging in physical activity [59]. Our intervention duration is consistent with exercise 
interventions for cancer survivors [60] and TC and Qigong RCTs with cancer survivors that 
1The study’s physical assessments (i.e., blood draw for cytokines, blood pressure assessed) were held during a morning session one 
week before the classes began, before participants’ randomization to study group, and during a morning session one week following 
the last study class. The sessions were held in a group format in which all the participants attended.
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have ranged from 45 minutes to 2 hours per session, from 2 to 5 times a week, for 5 to 12 
weeks [58]. Due to space limitations, the HEC classes were held at HCI, whereas the TCC 
sessions were held at a community senior center within two miles of HCI (i.e., held at 
similar times on the same three weekdays).
The TCC intervention was led by an experienced instructor who was accredited through 
teacher training provided by the TCC community. The TCC movements consist of 19 non-
strenuous movements and one standing pose: Rocking Motion, Bird Flaps its Wings, 
Around the Platter, Around the Platter variation, Bass Drum, Daughter on the Mountaintop, 
Carry the Ball, Push Pull, Pulling in Energy, Pulling Taffy, Pulling Taffy –Anchor, Pulling 
Taffy-Wrist Circles, Pulling Taffy-Perpetual Motion, Working the Pulley, Light at the Top 
of the Head, Joyous Breath, Passing Clouds, Six Healing Sounds, and Cosmic 
Consciousness Pose. Sessions began with a 20-minute warm-up that included seated 
meditation, self-massage of acupressure points, and light stretching, followed by 30 minutes 
of TCC movements and 10 minutes of closing movements. Participants were informed that 
all movements could be performed seated if needed. HEC served as an attention control 
group and focused on topics relevant to aging (e.g., successful aging, pain, sleep changes, & 
social roles), with the majority of topics spanning two classes each. These classes were led 
by a variety of health specialists (i.e., gerontological oncologist, nutritionist, physical 
therapist, social worker, & health promotion specialists). Make-up classes were not offered 
to participants; however, the TCC participants received a DVD of the instructor performing 
the TCC movements (data on home practice was not collected). Class attendance was 
encouraged by the research coordinator (i.e., missed classes were followed up with a phone 
call to the participant) and attendance was recorded by study staff. Participants were asked 
not to begin new physical activity during the study.
Data Analysis
Pearson chi-square tests for categorical data and Wilcoxon tests for continuous data (due to 
data skewness) were used to compare study groups on baseline sociodemographics. The 
cortisol and inflammatory cytokine data were log-transformed due to appreciable skewness. 
Analysis of covariance (ANCOVA), controlling for baseline, compared the TCC and HEC 
groups at post-intervention on BP, salivary cortisol, and inflammatory cytokines. Post-hoc 
analyses were conducted with Pearson bivariate correlations and Fishers Exact tests. 
Analyses were conducted on participants with complete data at baseline and post-
intervention. In this feasibility trial, intent-to-treat analyses were not conducted because we 
did not have post-intervention data on participants who withdrew from the study to conduct 
complete case analysis and our sample size was too small to conduct multiple imputation 




As shown in the CONSORT diagram (Figure 1), we randomized 63 survivors to a study 
group and 54 completed the intervention. The overall retention rate for the intervention (i.e., 
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the proportion who remained enrolled) was 86% and did not significantly differ between 
study groups [TCC = 91% (3 out of 32 withdrew), HEC = 81% (6 out of 31 withdrew); 
p=0.44]. The most common reasons for withdrawing after randomization were work-related 
reasons and time commitment. The overall class attendance was 81% and did not differ 
between study groups (TCC=79%, HEC=83%; p=0.36). There were no adverse events to 
report. We have also reported details of the trial’s feasibility and acceptability in a prior 
manuscript [54].
Sociodemographics and Medical Characteristics
The study groups did not significantly differ in baseline sociodemographics and medical 
characteristics (Table 1). The median age was 66.54 years (55 – 84 years) and the majority 
had a history of breast cancer (80% of the N=54 included in data analysis); other types 
included colorectal, cervical, uterine, thyroid, bladder, and nasopharyngeal. The number of 
years since cancer diagnosis or treatment did not differ between study groups (Table 1, p’s>.
05). Importantly, the study groups were balanced on cancer treatments (including hormone 
treatment) and self-reported use of medications (i.e., cardiovascular, diabetic, 
antidepressants, & corticosteroids; p’s>.05). Participants reported an average of 1.90 
(SD=1.22) comorbidities (i.e., depression, hypertension, heart attack, diabetes, arthritis, or 
chronic obstructive pulmonary disease), and the total number of comorbidities did not differ 
between groups (p=0.85). We did not include cancer treatments, medication use, or 
comorbidities as covariates in the model because these were balanced between study groups 
and the study was underpowered to include these as covariates. In our main analysis, we 
controlled for baseline assessments of the variable of interest (i.e., blood pressure, cortisol, 
& cytokines) to control experimental error and increase the precision in which the 
intervention effect could be measured.
Blood Pressure
ANCOVAs, controlling for baseline, examined if the study groups’ SBP and DBP differed 
at post-intervention. Complete data for analysis was available for 29 TCC participants and 
24 HEC participants. The TCC group had significantly lower SBP at post-intervention than 
the HEC group (TCC adjM=119.00, SE=2.81; HEC adjM =132.57, SE=3.09, p=0.002; 
Figure 2).2 The study groups did not significantly differ for DBP (TCC adjM =79.62, 
SE=2.18; HEC adjM =79.69, SE=2.40, p=0.98).
Cortisol
The analyses included participants with complete data for all five collection samples (TCC 
n=20, HEC n=19). Nine participants (TCC n=6, HEC n=3) were missing at least one of the 
five samples due to insufficient saliva production. Then, four participants (TCC n=2, HEC 
n=2) with high cortisol profiles were excluded because of values greater than 75 nmol/L, 
which research has suggested removal of as the high levels may be due to altered pH-values 
or suspected blood contamination [61, 62]. Two participants (one each in TCC and HEC) 
2We also conducted an ANCOVA subanalysis for SBP that excluded the five TCC participants who reported a history of a heart 
attack and found similar results (p=0.004).
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whose first (awakening) and second (30-minutes after awakening) sample collection times 
were at least 3 hours apart were excluded from analysis.
ANCOVA results for the log-transformed cortisol awakening response (CAR; difference 
between awakening and 30 minutes after awakening), controlling for CAR baseline, 
revealed that the study groups did not significantly differ at post-intervention (TCC adjM 
=0.37, SE=0.13; HEC adjM =0.46, SE=0.13; p=0.63). Similar results were found when the 
analysis included participants whose first and second samples were at least 3 hours apart 
(p=0.19). Next, we examined whether the study groups differed in their diurnal slopes (i.e., 
the 30 minutes after awakening sample to the 10 pm sample) and did not find significant 
group differences (TCC b = −0.69, HEC b = −0.59; p=0.28). Finally, we compared the 
groups at post-intervention on their log-transformed cortisol area-under-the-curve values 
(AUC, calculated with the Trapezoid rule), controlling for baseline cortisol AUC.3 Results 
indicated that the TCC group had significantly lower post-intervention cortisol AUC than 
the HEC group (TCC adjM =24.65, SE=1.52; HEC adjM =29.95, SE=1.56, p=0.02; Figure 
2).
Inflammatory Cytokines
Complete data for analysis of the inflammatory cytokines was available for 28 TCC 
participants and 24 HEC participants because two participants (one each in TCC and HEC) 
did not provide blood samples. ANCOVAs, controlling for baseline, were conducted on log-
transformed pro- and anti-inflammatory cytokines (IL-12, IL-6, TNF-α, IL-10, & IL-4) at 
post-intervention. Results indicated that the study groups did not significantly differ among 
the pro- and anti-inflammatory cytokines at post-intervention (all p’s>.05). Summary data of 
the log-transformed values at baseline and post-intervention are presented in Table 2.
Post-hoc Analyses
In our prior publication, we reported on SF-36 QOL outcomes [54]. For exploratory 
purposes, we examined associations of changes in the biomarker outcomes (blood pressure, 
inflammatory cytokines, AUC cortisol) with changes in the mental (MCS) and physical 
component summary (PCS) scores for each group using Pearson bivariate correlations. 
These results did not reveal significant associations of the biomarkers with PCS or MCS for 
either the TCC or HEC group (all p ’s >0.05).
Finally, older age is associated with a high-risk biological profile (e.g., higher BP & chronic 
lowgrade inflammation) due to more comorbidities, which could have influenced our 
biomarker outcomes. To examine this, we divided the sample into a younger (55 to 64 years 
of age, n=21) and an older age group (> 65 years of age, n=33), and compared these age 
groups on reported baseline comorbidities (i.e., hypertension, heart attack history, diabetes, 
arthritis, depression, & COPD) with Fishers Exact tests. These results did not reveal any age 
differences for proportion of comorbidities among the younger and older age groups (p’s> 
0.05). We also conducted Pearson bivariate correlations to examine the associations of age 
3The sample times for the cortisol AUC analysis were fixed at 7:00 am, 7:30 am, 12:00 noon, 5:00 pm, and 10:00 pm. We recognize 
that this is a study limitation and that these results should be viewed as preliminary.
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with baseline blood pressure, cortisol (i.e., CAR, AUC), and the inflammatory cytokines. 
These results were also nonsignificant (p’s> 0.05), suggesting that older age was not 
associated with our biomarker outcomes.
Discussion
Our 12-week TCC intervention for senior female cancer survivors was associated with lower 
levels of SBP and cortisol AUC at post-intervention in the TCC group compared to the HEC 
group. These SBP findings are consistent with other TC interventions of similar length that 
have found significant BP reductions in different populations (i.e., general and older adults, 
cardiovascular disease patients) [26, 21, 27, 63]. Although we did not find reductions in 
DBP, we view the reductions in SBP as noteworthy because isolated SBP hypertension is 
the most common type of uncontrolled hypertension in older adults and it is associated with 
an increased risk for coronary heart disease, stroke, and end-stage renal disease [50]. 
Reduced BP is also highly relevant for senior cancer survivors considering that 
cardiovascular disease is a leading cause of morbidity and mortality in long-term survivors 
[49, 10]. Thus, it is essential that senior cancer survivors maintain a normotensive status in 
order to manage their cardiovascular risk and TC exercise may be offered as a non-
pharmacological intervention for managing this risk.
In regards to the cortisol outcomes, there are a limited number of TC interventions that have 
examined cortisol in cancer survivors and these studies did not find significant differences 
compared to a control group [64, 36]. Similar to Chen and colleagues (2013), we did not 
find that our study groups differed on their slopes or CAR; however, we found that AUC 
cortisol was lower for the TCC group than the HEC group. This may be an important 
outcome considering that elevated AUC cortisol has been found in advanced-stage 
depressed cancer patients (ovarian cancer) [65] and elevated cortisol levels are an indicator 
of early mortality for metastatic breast cancer patients [66].
We did not find an intervention effect for the inflammatory cytokine levels, which is 
consistent with cytokine outcomes reported in prior TC studies conducted with healthy older 
adults and breast cancer survivors [30, 36, 28]. One speculation for our null finding is that 
TC has a limited influence on senior cancer survivors’ inflammatory cytokines due to a 
complex interaction of factors associated with aging (chronic low-grade inflammation), 
existence of comorbidities, and cancer treatment late effects that can result in immune 
dysregulation [39, 48, 43, 44, 38]. However, exercise research with older adults suggests 
there is a dose-response relationship between regular exercise and reductions in age-related 
inflammation [67]. Particularly, C-reactive protein (CRP, downstream inflammatory marker) 
tends to be the most consistently responsive to exercise, whereas, the evidence for 
inflammatory cytokines, such as IL-6 and TNF-α, has been less consistent [67]. Likewise, 
TC studies with older adults and cancer survivors have reported reductions in CRP [29, 68], 
but normalized IL-6 levels have only been found among older adults who had high baseline 
levels, with no effects for other inflammatory cytokines [30]. Another speculation is that the 
intervention did not result in increased aerobic fitness or fat loss (i.e., fat mass & adipose 
tissue), which could have led to reductions in inflammatory cytokines [67]. A TC 
intervention with breast cancer survivors did find associations between decreased fat mass 
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and increased fat-free mass with increased IL-6 (muscle-derived IL-6 has anti-inflammatory 
effects) and decreased IL-2 levels [28]. Future TC research with senior cancer survivors 
would benefit from including downstream markers of the inflammatory process, such as 
CRP, and assessments of aerobic fitness and fat loss (i.e., fat mass & adipose tissue) to allow 
the examination of potential inflammatory mechanisms.
Our study has a few limitations to be noted. First, the mechanisms that may have driven the 
SBP and cortisol AUC outcomes are unknown. We can speculate that our findings may have 
been a result of psychosocial processes (e.g., stress reductions), increases in physical 
activity, or the combined effects of these. All of these are associated with improved chronic 
disease risk factors [69, 15, 18]. However, we did not find any associations of changes in 
mental-health or physical-health QOL with changes in the biomarker outcomes. A review on 
TC RCTs for patients with cardiovascular conditions indicated that TC was associated with 
greater reductions in BP when compared to a health education control or to no treatment, but 
outcomes were equivalent to physical exercise [63]. This suggests that TC may be 
associated with reductions in BP due to physical activity. Future assessments of 
psychosocial factors (i.e., stress) and objective fitness outcomes (i.e., aerobic fitness & fat 
loss) may help clarify the underlying mechanisms behind TCC’s effects.
Another limitation is that the outcomes were limited to one-week post-intervention. In this 
feasibility trial, we were interested in the acute outcomes of TCC on senior female 
survivors’ chronic disease risk factors. However, a 2-month or longer follow-up may reveal 
whether TC practice and these BP and cortisol outcomes can be maintained or additional 
biomarker improvements observed (i.e., inflammatory cytokines). Very few studies have 
examined the long-term effects of mind-body activities on biomarker levels, with the 
exception of an 8-week stress-reduction intervention with yoga that found continued 
reductions in cortisol and inflammatory cytokines over a one year follow-up period [70]. As 
noted, future studies should assess whether similar ongoing physiological benefits would be 
observed in senior cancer survivors who are more long-term TC practitioners, as this may 
have implications for the management of chronic diseases.
Additionally, these findings are limited to older female, mainly Caucasian, cancer survivors, 
thus may not be generalizable to older male cancer survivors or older racial/ethnic minority 
survivors. Future TCC studies should examine whether similar BP and cortisol outcomes are 
observed with prostate cancer survivors, a population that is at an increased risk for diabetes 
and heart disease due to the side effects of androgen deprivation therapy [71]. These 
findings should also be examined in more racially/ethnically diverse survivor populations. 
We are not aware of any Tai Chi trials that have examined the uptake or efficacy of Tai Chi 
for improving biomarker outcomes in ethnic minority survivors. Additionally, these findings 
are limited to senior female survivors with limitations in physical functioning. Other TC 
studies with breast cancer survivors that did not limit by physical functioning have found 
beneficial outcomes in functional capacity [33, 34], insulin levels [28], QOL [33, 36, 34] 
and bone metabolism [35].
A final limitation is that the reliability of our cortisol results is limited by a single-day 
collection, rather than a multiple-day collection. Given the day-to-day variability in cortisol 
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[72], future studies should aim to replicate these findings by including two to three days of 
salivary cortisol collections. Despite these issues, we view our findings for lower cortisol 
AUC in the TCC group as promising in light of prior studies that found elevated cortisol 
levels predicted poor survival outcomes for cancer survivors [73, 66].
In summary, a major strength of our study is that we have demonstrated that TCC 
interventions have the potential to improve chronic disease risk factors (i.e., SBP, cortisol) 
in senior cancer survivors with physical functioning limitations. This has important 
implications for older cancer survivors who have increased morbidity and mortality risks 
due to common chronic diseases, particularly cardiovascular disease [9, 3, 10]. However, 
our results should also be viewed as preliminary due to the small and heterogeneous sample 
of senior survivors in this feasibility trial. Future large-scale efficacy trials are needed to 
replicate our findings across a wider range of older cancer survivors (i.e., both men & 
women, more ethnically diverse populations), examine biomarker outcomes at longer 
follow-up periods, and to help determine the mechanisms (i.e., psychosocial factors and/or 
improved physical fitness and fat loss) responsible for these outcomes. These findings can 
help determine effective behavioral interventions for the prevention and management of 
chronic diseases in older cancer survivors.
Acknowledgments
Preparation of this manuscript was funded by a National Institutes of Health National Center for Complementary 
and Alternative Medicine Research Fellowship in Complementary and Alternative Medicine (T-32 AT00378) at the 
University of North Carolina for the first author (R.A. Campo). The Health Education & Active Living in Surviving 
Seniors (HEALS) Project was funded by a grant from the National Cancer Institute (R21CA135250) awarded to Dr. 
Anita Kinney and by the Huntsman Cancer Foundation. Additional support was provided by the Shared Resources 
(P30 CA042014) for use of the Research Informatics Shared Resource and the Study Design and Biostatistics 
Center. Additionally, the Linda B. and Robert B. Wiggins Wellness-Survivorship Center at Huntsman Cancer 
Institute provided support for the study physical assessments. This content is solely the responsibility of the authors 
and does not necessarily represent the official views of the funding and supporting agencies. The authors have no 
conflicts of interest to report. We thank the Associated Regional and University Pathologists’ Institute for Clinical 
and Experimental Pathology at the University of Utah and the Kirschbaum Biopsychology Laboratory at Technical 
University of Dresden, Germany for assays of the inflammatory cytokines and cortisol samples, respectively.
References
1. Parry C, Kent EE, Mariotto AB, Alfano CM, Rowland JH. Cancer survivors: a booming population. 
Cancer Epidemiol Biomarkers Prev. 2011; 20(10):1996–2005.10.1158/1055-9965.EPI-11-0729 
[PubMed: 21980007] 
2. ACS. Cancer Treatment and Survivorship Facts & Figures 2012–2013. Atlanta: American Cancer 
Society; 2012. 
3. Byers T, Patnaik JL. Missed opportunities for chronic disease prevention after breast cancer. 
Womens Health (Lond Engl). 2011; 7(6):619–21.10.2217/whe.11.66 [PubMed: 22040202] 
4. Demark-Wahnefried W, Pinto BM, Gritz ER. Promoting health and physical function among cancer 
survivors: potential for prevention and questions that remain. JClinOncol. 2006; 24(32):5125–31.
5. Rao AV, Demark-Wahnefried W. The older cancer survivor. Crit RevOncolHematol. 2006; 60(2):
131–43.
6. Rowland JH, Yancik R. Cancer survivorship: the interface of aging, comorbidity, and quality care. J 
NatlCancer Inst. 2006; 98(8):504–5.
7. Hewitt M, Rowland JH, Yancik R. Cancer survivors in the United States: age, health, and disability. 
J GerontolA BiolSciMed Sci. 2003; 58(1):82–91.
Campo et al. Page 11






















8. Yancik R, Ganz PA, Varricchio CG, Conley B. Perspectives on comorbidity and cancer in older 
patients: approaches to expand the knowledge base. J Clin Oncol. 2001; 19(4):1147–51. [PubMed: 
11181680] 
9. Patnaik JL, Byers T, Diguiseppi C, Denberg TD, Dabelea D. The influence of comorbidities on 
overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst. 2011; 
103(14):1101–11.10.1093/jnci/djr188 [PubMed: 21719777] 
10. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes 
with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a 
retrospective cohort study. Breast Cancer Res. 2011; 13(3):R64.10.1186/bcr2901 [PubMed: 
21689398] 
11. Yusuf SW, Sami S, Daher IN. Radiation-induced heart disease: a clinical update. Cardiology 
research and practice. 2011; 2011:317659.10.4061/2011/317659 [PubMed: 21403872] 
12. Weaver KE, Foraker RE, Alfano CM, Rowland JH, Arora NK, Bellizzi KM, et al. Cardiovascular 
risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a 
gap in survivorship care? J Cancer Surviv. 2013; 7(2):253–61.10.1007/s11764-013-0267-9 
[PubMed: 23417882] 
13. Haque R, Prout M, Geiger AM, Kamineni A, Thwin SS, Avila C, et al. Comorbidities and 
cardiovascular disease risk in older breast cancer survivors. Am J Manag Care. 2014; 20(1):86–92. 
[PubMed: 24512167] 
14. Keating NL, Norredam M, Landrum MB, Huskamp HA, Meara E. Physical and mental health 
status of older long-term cancer survivors. J Am GeriatrSoc. 2005; 53(12):2145–52.
15. Warburton DE, Nicol CW, Bredin SS. Health benefits of physical activity: the evidence. CMAJ. 
2006; 174(6):801–9.10.1503/cmaj.051351 [PubMed: 16534088] 
16. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival 
after breast cancer diagnosis. JAMA. 2005; 293(20):2479–86. [PubMed: 15914748] 
17. Irwin ML, Smith AW, McTiernan A, Ballard-Barbash R, Cronin K, Gilliland FD, et al. Influence 
of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: the health, 
eating, activity, and lifestyle study. J Clin Oncol. 2008; 26(24):3958–64. doi:26/24/3958 [pii] 
10.1200/JCO.2007.15.9822. [PubMed: 18711185] 
18. Courneya KS, Vallance JK, McNeely ML, Karvinen KH, Peddle CJ, Mackey JR. Exercise issues 
in older cancer survivors. Crit Rev Oncol Hematol. 2004; 51(3):249–61. doi:10.1016/j.critrevonc.
2004.05.001 S1040842804000848[pii]. [PubMed: 15331082] 
19. Irwin ML, McTiernan A, Bernstein L, Gilliland FD, Baumgartner R, Baumgartner K, et al. 
Physical activity levels among breast cancer survivors. Med SciSports Exerc. 2004; 36(9):1484–
91.
20. Larkey L, Jahnke R, Etnier J, Gonzalez J. Meditative movement as a category of exercise: 
implications for research. J Phys Act Health. 2009; 6(2):230–8. [PubMed: 19420401] 
21. Rogers CE, Larkey LK, Keller C. A review of clinical trials of tai chi and qigong in older adults. 
West J Nurs Res. 2009; 31(2):245–79. doi:31/2/245 [pii] 10.1177/0193945908327529. [PubMed: 
19179544] 
22. Hui SS, Woo J, Kwok T. Evaluation of energy expenditure and cardiovascular health effects from 
Tai Chi and walking exercise. Hong Kong medical journal = Xianggang yi xue za zhi / Hong 
Kong Academy of Medicine. 2009; 15(Suppl 2):4–7.
23. Fontana JA, Colella C, Wilson BR, Baas L. The energy costs of a modified form of T’ai Chi 
exercise. Nurs Res. 2000; 49(2):91–6.10.1097/00006199-200003000-00005 [PubMed: 10768585] 
24. Jahnke R, Larkey L, Rogers C, Etnier J, Lin F. A comprehensive review of health benefits of 
qigong and tai chi. American journal of health promotion : AJHP. 2010; 24(6):e1–e25.10.4278/
ajhp.081013-LIT-248 [PubMed: 20594090] 
25. Motivala SJ, Sollers J, Thayer J, Irwin MR. Tai Chi Chih acutely decreases sympathetic nervous 
system activity in older adults. J Gerontol A Biol Sci Med Sci. 2006; 61(11):1177–80. [PubMed: 
17167159] 
26. Yeh GY, Wang C, Wayne PM, Phillips RS. The effect of tai chi exercise on blood pressure: a 
systematic review. Prev Cardiol. 2008; 11(2):82–9. [PubMed: 18401235] 
Campo et al. Page 12






















27. Lan C, Chen SY, Wong MK, Lai JS. Tai Chi Chuan Exercise for Patients with Cardiovascular 
Disease. Evid Based Complement Alternat Med. 2013; 2013:983208.10.1155/2013/983208 
[PubMed: 24348732] 
28. Janelsins MC, Davis PG, Wideman L, Katula JA, Sprod LK, Peppone LJ, et al. Effects of Tai Chi 
Chuan on insulin and cytokine levels in a randomized controlled pilot study on breast cancer 
survivors. Clin Breast Cancer. 2011; 11(3):161–70. doi:S1526-8209(11)00014-0 [pii] 10.1016/
j.clbc.2011.03.013. [PubMed: 21665136] 
29. Lavretsky H, Alstein LL, Olmstead RE, Ercoli LM, Riparetti-Brown M, Cyr NS, et al. 
Complementary use of tai chi chih augments escitalopram treatment of geriatric depression: a 
randomized controlled trial. Am J Geriatr Psychiatry. 2011; 19(10):839–50.10.1097/JGP.
0b013e31820ee9ef [PubMed: 21358389] 
30. Irwin MR, Olmstead R. Mitigating cellular inflammation in older adults: a randomized controlled 
trial of Tai Chi Chih. Am J Geriatr Psychiatry. 2012; 20(9):764–72.10.1097/JGP.
0b013e3182330fd3 [PubMed: 21934474] 
31. Irwin MR, Olmstead R, Oxman MN. Augmenting immune responses to varicella zoster virus in 
older adults: a randomized, controlled trial of Tai Chi. J Am GeriatrSoc. 2007; 55(4):511–7.
32. Irwin MR, Pike JL, Cole JC, Oxman MN. Effects of a behavioral intervention, Tai Chi Chih, on 
varicella-zoster virus specific immunity and health functioning in older adults. Psychosom Med. 
2003; 65(5):824–30. [PubMed: 14508027] 
33. Mustian KM, Palesh OG, Flecksteiner SA. Tai Chi Chuan for breast cancer survivors. Med Sport 
Sci. 2008; 52:209–17. doi:10.1159/000134301 [pii] 10.1159/000134301. [PubMed: 18487900] 
34. Mustian KM, Katula JA, Zhao H. A pilot study to assess the influence of tai chi chuan on 
functional capacity among breast cancer survivors. J SupportOncol. 2006; 4(3):139–45.
35. Peppone LJ, Mustian KM, Janelsins MC, Palesh OG, Rosier RN, Piazza KM, et al. Effects of a 
structured weight-bearing exercise program on bone metabolism among breast cancer survivors: a 
feasibility trial. Clin Breast Cancer. 2010; 10(3):224–9. doi:S1526-8209(11)70032-5 [pii] 10.3816/
CBC.2010.n.030. [PubMed: 20497921] 
36. Sprod LK, Janelsins MC, Palesh OG, Carroll JK, Heckler CE, Peppone LJ, et al. Health-related 
quality of life and biomarkers in breast cancer survivors participating in tai chi chuan. J Cancer 
Surviv. 2012; 6(2):146–54.10.1007/s11764-011-0205-7 [PubMed: 22160628] 
37. Mustian KM, Katula JA, Gill DL, Roscoe JA, Lang D, Murphy K. Tai Chi Chuan, health-related 
quality of life and self-esteem: a randomized trial with breast cancer survivors. Support Care 
Cancer. 2004; 12(12):871–6.10.1007/s00520-004-0682-6 [PubMed: 15599776] 
38. Irwin M, Pike J, Oxman M. Shingles Immunity and Health Functioning in the Elderly: Tai Chi 
Chih as a Behavioral Treatment. EvidBasedComplement AlternatMed. 2004; 1(3):223–32.
39. Lutgendorf SK, Costanzo ES. Psychoneuroimmunology and health psychology: an integrative 
model. Brain BehavImmun. 2003; 17(4):225–32.
40. Friedman EM, Irwin MR. Modulation of immune cell function by the autonomic nervous system. 
Pharmacol Ther. 1997; 74(1):27–38. [PubMed: 9336014] 
41. Elenkov IJ. Glucocorticoids and the Th1/Th2 balance. Ann N Y Acad Sci. 2004; 1024:138–
46.10.1196/annals.1321.010 [PubMed: 15265778] 
42. Cohen S, Janicki-Deverts D, Doyle WJ, Miller GE, Frank E, Rabin BS, et al. Chronic stress, 
glucocorticoid receptor resistance, inflammation, and disease risk. Proc Natl Acad Sci U S A. 
2012; 109(16):5995–9.10.1073/pnas.1118355109 [PubMed: 22474371] 
43. Licastro F, Candore G, Lio D, Porcellini E, Colonna-Romano G, Franceschi C, et al. Innate 
immunity and inflammation in ageing: a key for understanding age-related diseases. Immunity & 
ageing : I & A. 2005; 2:8.10.1186/1742-4933-2-8 [PubMed: 15904534] 
44. Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. 
Immunology. 2007; 120(4):435–46.10.1111/j.1365-2567.2007.02555.x [PubMed: 17313487] 
45. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et al. Markers 
of inflammation and cardiovascular disease: application to clinical and public health practice: A 
statement for healthcare professionals from the Centers for Disease Control and Prevention and the 
American Heart Association. Circulation. 2003; 107(3):499–511. [PubMed: 12551878] 
Campo et al. Page 13






















46. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420(6917):860–7.10.1038/
nature01322 [PubMed: 12490959] 
47. Cesari M, Penninx BW, Pahor M, Lauretani F, Corsi AM, Rhys Williams G, et al. Inflammatory 
markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci 
Med Sci. 2004; 59(3):242–8. [PubMed: 15031308] 
48. Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol. 
2004; 39(5):687–99. doi:10.1016/j.exger.2004.01.009 S0531556504000531 [pii]. [PubMed: 
15130663] 
49. Daher IN, Daigle TR, Bhatia N, Durand JB. The prevention of cardiovascular disease in cancer 
survivors. Texas Heart Institute journal / from the Texas Heart Institute of St Luke’s Episcopal 
Hospital, Texas Children’s Hospital. 2012; 39(2):190–8.
50. He J, Whelton PK. Elevated systolic blood pressure and risk of cardiovascular and renal disease: 
overview of evidence from observational epidemiologic studies and randomized controlled trials. 
Am Heart J. 1999; 138(3 Pt 2):211–9. [PubMed: 10467215] 
51. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of 
hypertension, 1988–2008. JAMA. 2010; 303(20):2043–50.10.1001/jama.2010.650 [PubMed: 
20501926] 
52. Lutgendorf SK, Sood AK. Biobehavioral factors and cancer progression: physiological pathways 
and mechanisms. Psychosom Med. 2011; 73(9):724–30.10.1097/PSY.0b013e318235be76 
[PubMed: 22021459] 
53. Elenkov IJ, Chrousos GP. Stress hormones, proinflammatory and antiinflammatory cytokines, and 
autoimmunity. Ann N Y Acad Sci. 2002; 966:290–303. [PubMed: 12114286] 
54. Campo RA, O’Connor K, Light KC, Nakamura Y, Lipschitz DL, LaStayo PC, et al. Feasibility and 
acceptability of a Tai Chi Chih randomized controlled trial in senior female cancer survivors. 
Integrative cancer therapies. 2013; 12(6):464–74.10.1177/1534735413485418 [PubMed: 
23620504] 
55. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting 
parallel group randomised trials. Int J Surg. 2011; 9(8):672–7.10.1016/j.ijsu.2011.09.004 
[PubMed: 22019563] 
56. Martins TB, Pasi BM, Pickering JW, Jaskowski TD, Litwin CM, Hill HR. Determination of 
cytokine responses using a multiplexed fluorescent microsphere immunoassay. Am J Clin Pathol. 
2002; 118(3):346–53.10.1309/N0T6-C56B-GXB2-NVFB [PubMed: 12219776] 
57. Hill HR, Martins TB. The flow cytometric analysis of cytokines using multi-analyte fluorescence 
microarray technology. Methods. 2006; 38(4):312–6.10.1016/j.ymeth.2005.11.014 [PubMed: 
16540344] 
58. Zeng Y, Luo T, Xie H, Huang M, Cheng AS. Health benefits of qigong or tai chi for cancer 
patients: a systematic review and meta-analyses. Complementary therapies in medicine. 2014; 
22(1):173–86.10.1016/j.ctim.2013.11.010 [PubMed: 24559833] 
59. Schutzer KA, Graves BS. Barriers and motivations to exercise in older adults. Prev Med. 2004; 
39(5):1056–61.10.1016/j.ypmed.2004.04.003 [PubMed: 15475041] 
60. Galvao DA, Newton RU. Review of exercise intervention studies in cancer patients. J Clin Oncol. 
2005; 23(4):899–909.10.1200/JCO.2005.06.085 [PubMed: 15681536] 
61. Kunz-Ebrecht SR, Kirschbaum C, Marmot M, Steptoe A. Differences in cortisol awakening 
response on work days and weekends in women and men from the Whitehall II cohort. 
Psychoneuroendocrinology. 2004; 29(4):516–28. doi:S0306453003000726 [pii]. [PubMed: 
14749096] 
62. Aardal E, Holm AC. Cortisol in saliva–reference ranges and relation to cortisol in serum. European 
journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical 
Chemistry Societies. 1995; 33(12):927–32.
63. Yeh GY, Wang C, Wayne PM, Phillips R. Tai chi exercise for patients with cardiovascular 
conditions and risk factors: A systematic review. J Cardiopulm Rehabil Prev. 2009; 29(3):152–60. 
doi:10.1097/HCR.0b013e3181a33379 01273116-200905000-00002 [pii]. [PubMed: 19471133] 
Campo et al. Page 14






















64. Chen Z, Meng Z, Milbury K, Bei W, Zhang Y, Thornton B, et al. Qigong improves quality of life 
in women undergoing radiotherapy for breast cancer: Results of a randomized controlled trial. 
Cancer. 201310.1002/cncr.27904
65. Lutgendorf SK, Weinrib AZ, Penedo F, Russell D, DeGeest K, Costanzo ES, et al. Interleukin-6, 
cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol. 2008; 26(29):4820–7. 
doi:JCO.2007.14.1978 [pii] 10.1200/JCO.2007.14.1978. [PubMed: 18779606] 
66. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of 
breast cancer survival. J Natl Cancer Inst. 2000; 92(12):994–1000. [PubMed: 10861311] 
67. Woods JA, Wilund KR, Martin SA, Kistler BM. Exercise, inflammation and aging. Aging and 
disease. 2012; 3(1):130–40. [PubMed: 22500274] 
68. Oh B, Butow PN, Mullan BA, Clarke SJ, Beale PJ, Pavlakis N, et al. Effect of medical Qigong on 
cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a 
randomized controlled trial. Support Care Cancer. 201110.1007/s00520-011-1209-6
69. Christian, LM.; Deichert, NT.; Gouin, J-P.; Graham, JE.; Kiecolt-Glaser, JK. Psychological 
influences on neuroendocrine and immune outcomes. In: Berntson, JTCGG., editor. Handbook of 
Neuroscience for the Behavioral Sciences Hoboken. New Jersey: John Wiley and Sons; 2009. p. 
1260-79.
70. Carlson LE, Speca M, Faris P, Patel KD. One year pre-post intervention follow-up of 
psychological, immune, endocrine and blood pressure outcomes of mindfulness-based stress 
reduction (MBSR) in breast and prostate cancer outpatients. Brain Behav Immun. 2007; 21(8):
1038–49. doi:S0889-1591(07)00085-2 [pii] 10.1016/j.bbi.2007.04.002. [PubMed: 17521871] 
71. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen 
deprivation therapy for prostate cancer. J Clin Oncol. 2006; 24(27):4448–56. doi:24/27/4448 [pii] 
10.1200/JCO.2006.06.2497. [PubMed: 16983113] 
72. Kirschbaum C, Hellhammer DH. Salivary cortisol in psychoneuroendocrine research: recent 
developments and applications. Psychoneuroendocrinology. 1994; 19(4):313–33. [PubMed: 
8047637] 
73. Abercrombie HC, Giese-Davis J, Sephton S, Epel ES, Turner-Cobb JM, Spiegel D. Flattened 
cortisol rhythms in metastatic breast cancer patients. Psychoneuroendocrinology. 2004; 29(8):
1082–92.10.1016/j.psyneuen.2003.11.003 [PubMed: 15219660] 
Campo et al. Page 15























Senior survivors’ have an increased risk for chronic diseases; however, TCC 
interventions may help reduce associated risk factors.
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Consort diagram of the Tai Chi Chih Randomized Controlled Trial.
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Systolic (top) and diastolic (middle) blood pressure and cortisol AUC (bottom) adjusted 
means for study groups (N=54) at baseline and post-intervention. Bars represent standard 
errors. *p<.05.
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Table 1





Age, Mdn years (range) 65.9 (55 – 82) 66.7 (59 – 84) 0.74
Non-Latino   27 (93%)   24 (96%) 0.64
White Race   28 (97%)   25 (100%) 0.54
Marital Status 0.35
 Married/living as married   21 (72%)   21 (84%)
 Not Marrieda     8 (23%)     4 (16%)
Educationb 0.06
 High School, some vocational school or college   20 (69%)   10 (42%)
 College degree/Post-grad     9 (31%)   14 (58%)
Religion 0.53
 Latter-Day-Saints/Mormon   12 (41%)   11 (44%)
 Other   17 (59%)   14 (56%)
Employment 0.37
 Employed     6 (21%)     8 (32%)
 Not employedc   23 (79%)   17 (68%)
Income ≥$50,000   16 (55%)     9 (33%) 0.30
Breast Cancer Diagnosis   22 (76%)   21 (84%) 0.38
Cancer Stage 0.11
 Stage I     9 (31%)     7 (29%)
 Stage II     7 (24%)   12 (50%)
 Stage III   13 (45%)     5 (21%)
Cancer Treatment
 Surgery   24 (83%)   22 (88%) 0.44
 Radiation   18 (62%)   15 (60%) 0.55
 Chemotherapy   16 (55%)   16 (64%) 0.58
 Current Hormone Treatment     7 (24%)     4 (16%) 0.35
Years Since Diagnosis Mdn (range)  9.0 (1 – 31)  8.0 (1 – 40) 0.50
Years Since Treatment Mdn (range)  8.5 (0 – 31)  6.0 (1 – 28) 0.28
Comorbiditiesd
 Heart Attack     5 (17%)     0 (0%) 0.05
 Arthritis   17 (59%)   16 (64%) 0.78
 Hypertension   16 (55%)   13 (52%) 1.00
 Depression   12 (41%)   11 (44%) 1.00
 Type 2 Diabetes Mellitus     2 (7%)     3 (12%) 0.65
 COPD     2 (7%)     4 (16%) 0.39
Note. Unless specified, values represent % (n). Wilcoxon tests were used for continuous data and Pearson Chi-square tests were used for 
categorical data. Fishers Exact test was used for categorical data with <5 per cell. Mdn =Median, TCC=Tai Chi Chih, HEC=Health Education 
Class, COPD=chronic obstructive pulmonary disease.
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a
Includes divorced, separated, never married, widowed.
b
One person’s data not reported in HEC.
c
Includes retired, unable to work, or unemployed.
d
Self-reported data from the question: “Have you ever been treated or told by a doctor that you have had any of the following…”.
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Table 2








 Baseline   3.5 (2.0, 8.3)   2.5 (1.6, 10.0)
 Post-Intervention   4.7 (3.3, 12.5)   3.7 (1.3, 7.4)
IL-6 pg/ml
 Baseline   6.8 (4.1, 24.2)   6.8 (3.9, 11.2)
 Post-Intervention   9.1 (4.3, 29.0)   5.3 (3.4, 8.2)
TNF-α pg/ml
 Baseline 19.7 (0, 101.5) 34.4 (0, 85.2)
 Post-Intervention 37.8 (0, 77.9) 45.1 (0, 109.1)
IL-4 pg/ml
 Baseline   1.0 (0.5, 3.1)   0.9 (0.6, 2.3)
 Post-Intervention   1.5 (0.6, 3.6)   1.1 (0.5, 2.2)
IL-10 pg/ml
 Baseline   5.9 (4.2, 19.8)   4.5 (3.4, 7.7)
 Post-Intervention   5.8 (4.3, 16.3)   5.0 (2.9, 7.7)
Note. Table includes participants with complete post-intervention data. TCC=Tai Chi Chih, HEC=Health Education Control, Mdn=Median, 
Q1=Lower Quartile, Q3= Upper Quartile, IL=Interleukin, TNF=Tumor Necrosis Factor.
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